Connecticut is currently home to 1248 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Haven, Hartford, Farmington and Stamford. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
NCT04373564
Recruiting
This study is a postmarketing requirement jointly carried out by four NDA holders (Bayer AG, Bracco, GE Healthcare and Guerbet) and the CRO IQVIA. The study aims to create detailed images of the organs and tissue of the human body during x-ray, CT-scan or MRI investigations, doctors are using contrast media (a kind of dye) which can be given to patients by injection into a blood vessel or by mouth. In this study researchers want to find out whether so called gadolinium-based contrast agents (G... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
05/15/2024
Locations: Yale University School of Medicine, New Haven, Connecticut
Conditions: Motor Function, Cognitive Function, Contrast Media
Register for Updates
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
NCT05543616
Recruiting
The purpose of this clinical trial is to learn about the safety, extent of the side effects, and immune responses of the study vaccine (called variant-adapted BNT162b2 RNA-based vaccine) in healthy children. The trial is divided into 5 individual studies or substudies based on age group and prior history of COVID-19 vaccinations. All participants in each of the 5 sub-studies will receive study vaccine as a shot depending on what group they are in. * Substudy A design: Phase 1 includes participa... Read More
Gender:
ALL
Ages:
Between 6 months and 11 years
Trial Updated:
05/13/2024
Locations: Yale University School of Medicine, New Haven, Connecticut
Conditions: SARS-CoV-2 Virus, Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19
Register for Updates
Development of Charcot Marie Tooth Disease (CMT) Pediatric Scale for Children With CMT
NCT01203085
Recruiting
The primary goal of this project is to develop and test a Charcot Marie Tooth disease (CMT) Pediatric Scale for use in evaluation in natural history CMT study.
Gender:
ALL
Ages:
21 years and below
Trial Updated:
05/09/2024
Locations: University of Connecticut/Connecticut Children's Medical Center, Hartford, Connecticut
Conditions: Charcot Marie Tooth Disease
Register for Updates
Genetics of Charcot Marie Tooth (CMT) - Modifiers of CMT1A, New Causes of CMT2
NCT01193088
Recruiting
This project includes two projects. One is looking for new genes that cause Charcot Marie Tooth disease (CMT). The other is looking for genes that do not cause CMT, but may modify the symptoms a person has.
Gender:
ALL
Ages:
All
Trial Updated:
05/09/2024
Locations: Connecticut Children's Medical Center, Hartford, Connecticut
Conditions: Charcot-Marie-Tooth Disease, Type Ia (Disorder), HMSN
Register for Updates
Natural History Evaluation of Charcot Marie Tooth Disease (CMT) Types CMT1B, CMT2A, CMT4A, CMT4C, and Others
NCT01193075
Recruiting
This is an observational longitudinal study to determine the natural history and genotype-phenotype correlations of disease causing mutations in Charcot Marie Tooth disease (CMT) type 1B (CMT1B), 2A (CMT2A), 4A (CMT4A), and 4C (CMT4C). The investigators will also be determine the capability of the newly developed CMT Pediatric Scale (CMT Peds scale) and the Minimal Dataset to measure impairment and perform longitudinal measurements in patients with multiple forms of CMT over a five year window
Gender:
ALL
Ages:
All
Trial Updated:
05/09/2024
Locations: University of Connecticut/Connecticut Children's Medical Center, Hartford, Connecticut
Conditions: Charcot Marie Tooth Disease
Register for Updates
PARTNER 3 Trial - Aortic Valve-in-Valve
NCT03003299
Recruiting
This study will assess the safety and effectiveness of the SAPIEN 3/SAPIEN 3 Ultra transcatheter heart valve (THV) in patients with a failing aortic bioprosthetic valve.
Gender:
ALL
Ages:
All
Trial Updated:
05/08/2024
Locations: Hartford Hospital, Hartford, Connecticut
Conditions: Aortic Stenosis, Aortic Stenosis, Severe
Register for Updates
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
NCT06399393
Recruiting
The purpose of this study is to compare the efficacy, safety, and tolerability of ide-cel with lenalidomide (LEN) maintenance to that of LEN maintenance alone in adult participants with Newly Diagnosed Multiple Myeloma (NDMM) who have achieved a suboptimal response post autologous stem cell transplantation (ASCT).
Gender:
All
Ages:
18 years and above
Trial Updated:
05/01/2024
Locations: Yale University School of Medicine, New Haven, Connecticut
Conditions: Multiple Myeloma
Register for Updates
Relationship Between Data Obtained With the LuGENE® Multiparameter Transcriptomics Blood Test and Clinical and Standard Laboratory Features of Patients With SLE (ReLATE)
NCT05845593
Recruiting
This is an open label study to determine the association of the data obtained with LuGENE®, a transcriptomic-based LDT, with standard evaluation of patients diagnosed with SLE, including clinical involvement, SLEDAI score, Physician Global Assessment (PGA) and standard laboratory measures, including ANA, anti-DNA, anti-RNP and complement components C3 and C4, as well as Patient Reported Outcomes capturing pain, fatigue and Health-Related Quality of Life. The test will be administered on one occa... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/01/2024
Locations: Yale School of Medicine, New Haven, Connecticut
Conditions: Lupus Erythematosus, Systemic
Register for Updates
Trial to Evaluate Safety, PD & PK of IV Study Drug, QN-302, in Pts w/ Advanced or Metastatic Solid Tumors
NCT06086522
Recruiting
Goal: learn about QN-302 in patients with solid tumors (metastatic, or advanced cancer). Main questions: * What does the study drug do to human body (Pharmacodynamics \[='PD'\]) * What does the body do to study drug (how processed in body (Pharmacokinetics \[='PK'\]) - Safety Study drug by intravenous infusion ('IV') once weekly for 3 weeks every 4-week 'cycle.' Study treatment continues as long as patient and their study doctor agree that study treatment is in the best interest of the patien... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2024
Locations: Yale, New Haven, Connecticut
Conditions: Solid Tumor
Register for Updates
A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies
NCT05753722
Recruiting
The goal of this Open-Label Study is to evaluate the safety and tolerability of PRTH-101 alone or in combination with pembrolizumab in adults with advance or metastatic solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: Yale Cancer Center, New Haven, Connecticut
Conditions: Advanced or Metastatic Solid Tumors
Register for Updates
FLIGHT Study for Childhood Chronic Illness
NCT06377384
Recruiting
The FLIGHT study is an open-label, single-arm, pilot and feasibility study of a personalized and multimodality intervention focusing upon modifiable lifestyle factors, environmental modifications, and transdisciplinary clinical care for children with chronic illness. A mixed methods outcomes evaluation will be performed. The primary goal of this study is to evaluate the most feasible and promising strategies to inform a more streamlined and scalable intervention in the future. Up to 14 participa... Read More
Gender:
ALL
Ages:
Between 2 years and 15 years
Trial Updated:
04/19/2024
Locations: Epidemic Answers, Windsor, Connecticut
Conditions: Chronic Illnesses, Multiple
Register for Updates
Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2
NCT05555589
Recruiting
The objective of this study is to compare the safety and efficacy of RGN-259 to placebo for the treatment of Neurotrophic Keratopathy (NK)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2024
Locations: Connecticut Eye Consultants, P.C. Danbury Eye Physicians & Surgeons, Danbury, Connecticut
Conditions: Neurotrophic Keratopathy
Register for Updates